<DOC>
	<DOCNO>NCT00540514</DOCNO>
	<brief_summary>The purpose study compare disease response Albumin-bound paclitaxel ( ABI-007 ) plus Carboplatin versus Taxol Carboplatin first-line therapy patient advance non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Albumin-bound Paclitaxel ( ABI-007 ) Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically confirm stage IIIB IV nonsmall cell lung cancer ( NSCLC ) Male nonpregnant nonlactating female , equal great age 18 If female patient childbearing potential , evidence regular menstrual period , must negative serum pregnancy test ( beta human chorionic gonadotropin [ Î²hCG ] ) document within 72 hour first administration study drug If sexually active , patient must agree utilize contraception consider adequate appropriate investigator No current active malignancy Radiographicallydocumented measurable disease ( define presence least 1 radiographically document measurable lesion ) Patients must receive prior chemotherapy treatment metastatic disease . Adjuvant chemotherapy permit provide cytotoxic chemotherapy complete 12 month prior start study Patient follow blood count baseline : Absolute neutrophil count ( ANC ) great equal 1.5x10^9/L Platelets great equal 100x10^9/L Hemoglobin ( Hgb ) great equal 9 g/dL Patient follow blood chemistry level baseline : Aspartate aminotransferase ( SGOT ) , alanine aminotransferase ( SGPT ) less equal 2.5 x upper limit normal range ( ULN ) less equal 5.0 x ULN liver metastasis ; Total bilirubin less equal ULN Creatinine less equal 1.5 mg/dL Expected survival great 12 week Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patient his/her legally authorize representative guardian inform nature study , agree participate study , sign Informed Consent form prior participation studyrelated activity Evidence active brain metastasis , include leptomeningeal involvement . Prior evidence brain metastasis permit treated stable therapy great equal 1 month The evidence disease nonmeasurable Patient preexist peripheral neuropathy Grade 2 , 3 , 4 ( per Common Terminology Criteria Adverse Events [ CTCAE ] Version 3 ) . Patient receive radiotherapy last 4 week , except nontarget lesion . Prior radiation target lesion permit clear progression lesion since radiation complete Patient clinically significant concurrent illness Patient receive treatment investigational drug within previous 4 week Patient history allergy hypersensitivity study drug Patient serious medical risk factor involve major organ system investigator considers unsafe patient receive experimental research drug Patient enrol clinical protocol investigational trial involve administration experimental therapy and/or therapeutic device .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Advanced Non-Small Cell Lung Cancer</keyword>
</DOC>